BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

19234

540222

LAURUSLABS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

LAURUS LABS LIMITED performance

Today’s low

Today’s high

₹ 650.15 ₹ 673.90
₹ 666.60

52 week low

52 week high

₹ 414.00 ₹ 681.00
₹ 666.60

Open Price

₹ 655.50

Prev. Close

₹ 666.75

Volume (Shares)

1292254.00

Total traded value

₹ 8614.16

Upper Circuit

₹ 733.40

Lower Circuit

₹ 600.10

info

LAURUS LABS LIMITED Share Price Update

As of the latest trading session, LAURUS LABS LIMITED share price is currently at ₹ 666.6, which is down by ₹ -0.15 from its previous closing. Today, the stock has fluctuated between ₹ 650.15 and ₹ 673.90. Over the past year, LAURUS LABS LIMITED has achieved a return of 51.67 %. In the last month alone, the return has been 11.98 %. Read More...

LAURUS LABS LIMITED fundamentals


  • Market cap (Cr)

    35,946.60

  • P/E Ratio (TTM)

    94.60

  • Beta

    1.28

  • Book Value / share

    84.63

  • Return on equity

    7.75%

  • EPS (TTM)

    6.31

  • Dividend yield

    0.18%

  • Net profit/quarter (Cr)

    251.90

info icon alternate text
  • Market cap (Cr)

    35,965.40

  • P/E Ratio (TTM)

    94.60

  • Beta

    1.20

  • Book Value / share

    84.63

  • Return on equity

    7.75%

  • EPS (TTM)

    6.31

  • Dividend yield

    0.18%

  • Net profit/quarter (Cr)

    251.90

info icon alternate text

LAURUS LABS LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 1650.01
Operating Expense 1391.96
Net Profit 251.90
Net Profit Margin (%) 15.26
Earnings Per Share (EPS) 4.68
EBITDA 466.99
Effective Tax Rate (%) 23.71
Particulars DEC 2024 (Values in Cr)
Revenue 1265.19
Operating Expense 1195.59
Net Profit 57.27
Net Profit Margin (%) 4.52
Earnings Per Share (EPS) 1.06
EBITDA 213.40
Effective Tax Rate (%) 25.35
Particulars SEP 2024 (Values in Cr)
Revenue 1184.85
Operating Expense 1138.65
Net Profit 42.44
Net Profit Margin (%) 3.58
Earnings Per Share (EPS) 0.79
EBITDA 193.72
Effective Tax Rate (%) 26.94
Particulars JUN 2024 (Values in Cr)
Revenue 1116.93
Operating Expense 1087.43
Net Profit 28.78
Net Profit Margin (%) 2.57
Earnings Per Share (EPS) 0.53
EBITDA 170.69
Effective Tax Rate (%) 25.82
Particulars MAR 2024 (Values in Cr)
Revenue 1414.52
Operating Expense 1274.30
Net Profit 121.32
Net Profit Margin (%) 8.57
Earnings Per Share (EPS) 2.25
EBITDA 295.20
Effective Tax Rate (%) 26.16
Particulars MAR 2025 (Values in Cr)
Revenue 5216.98
Operating Expense 4813.63
Net Profit 380.39
Net Profit Margin (%) 7.29
Earnings Per Share (EPS) 7.06
EBITDA 1044.80
Effective Tax Rate (%) 24.49
Particulars MAR 2024 (Values in Cr)
Revenue 4812.39
Operating Expense 4558.34
Net Profit 223.70
Net Profit Margin (%) 4.64
Earnings Per Share (EPS) 4.15
EBITDA 797.30
Effective Tax Rate (%) 25.79
Particulars MAR 2023 (Values in Cr)
Revenue 5773.45
Operating Expense 4737.97
Net Profit 760.38
Net Profit Margin (%) 13.17
Earnings Per Share (EPS) 14.14
EBITDA 1497.71
Effective Tax Rate (%) 27.68
Particulars MAR 2022 (Values in Cr)
Revenue 4707.04
Operating Expense 3753.18
Net Profit 750.09
Net Profit Margin (%) 15.93
Earnings Per Share (EPS) 13.97
EBITDA 1306.75
Effective Tax Rate (%) 23.10
Particulars MAR 2021 (Values in Cr)
Revenue 4768.72
Operating Expense 3521.41
Net Profit 956.11
Net Profit Margin (%) 20.04
Earnings Per Share (EPS) 17.85
EBITDA 1537.19
Effective Tax Rate (%) 24.98
Particulars MAR 2025 (Values in Cr)
Book Value / Share 82.94
ROE % 7.36
ROCE % 8.80
Total Debt to Total Equity 0.62
EBITDA Margin 19.33
Particulars MAR 2024 (Values in Cr)
Book Value / Share 76.28
ROE % 4.13
ROCE % 6.31
Total Debt to Total Equity 0.56
EBITDA Margin 15.95
Particulars MAR 2023 (Values in Cr)
Book Value / Share 74.96
ROE % 21.56
ROCE % 21.78
Total Debt to Total Equity 0.51
EBITDA Margin 26.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 62.37
ROE % 27.99
ROCE % 24.59
Total Debt to Total Equity 0.55
EBITDA Margin 29.13
Particulars MAR 2021 (Values in Cr)
Book Value / Share 48.41
ROE % 45.05
ROCE % 37.78
Total Debt to Total Equity 0.59
EBITDA Margin 32.71
Particulars MAR 2025 (Values in Cr)
Book Value / Share 84.64
ROE % 7.75
ROCE % 9.14
Total Debt to Total Equity 0.51
EBITDA Margin 18.91
Particulars MAR 2024 (Values in Cr)
Book Value / Share 78.06
ROE % 5.41
ROCE % 7.34
Total Debt to Total Equity 0.46
EBITDA Margin 16.57
Particulars MAR 2023 (Values in Cr)
Book Value / Share 75.31
ROE % 20.43
ROCE % 21.62
Total Debt to Total Equity 0.45
EBITDA Margin 25.94
Particulars MAR 2022 (Values in Cr)
Book Value / Share 63.05
ROE % 24.59
ROCE % 22.71
Total Debt to Total Equity 0.50
EBITDA Margin 27.76
Particulars MAR 2021 (Values in Cr)
Book Value / Share 50.54
ROE % 42.23
ROCE % 37.11
Total Debt to Total Equity 0.54
EBITDA Margin 32.23
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 144.21
Total Assets 9335.57
Total Liabilities 9335.57
Total Equity 4602.52
Share Outstanding 539252491
Price to Book Ratio 7.25
Return on Assets (%) 3.83
Return on Capital (%) 4.91
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 141.65
Total Assets 8387.03
Total Liabilities 8387.03
Total Equity 4115.57
Share Outstanding 538965858
Price to Book Ratio 5.02
Return on Assets (%) 1.91
Return on Capital (%) 2.42
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 48.46
Total Assets 7660.40
Total Liabilities 7660.40
Total Equity 4048.66
Share Outstanding 538650925
Price to Book Ratio 3.89
Return on Assets (%) 10.31
Return on Capital (%) 13.12
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 75.94
Total Assets 6968.04
Total Liabilities 6968.04
Total Equity 3359.05
Share Outstanding 537359335
Price to Book Ratio 9.36
Return on Assets (%) 11.87
Return on Capital (%) 16.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 48.46
Total Assets 5750.69
Total Liabilities 5750.69
Total Equity 2600.70
Share Outstanding 536602385
Price to Book Ratio 7.16
Return on Assets (%) 17.10
Return on Capital (%) 24.26
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 50.64
Total Assets 8586.75
Total Liabilities 8586.75
Total Equity 4563.95
Share Outstanding 539252491
Price to Book Ratio 7.25
Return on Assets (%) 4.42
Return on Capital (%) 5.52
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 42.92
Total Assets 7667.48
Total Liabilities 7667.48
Total Equity 4207.05
Share Outstanding 538965858
Price to Book Ratio 5.02
Return on Assets (%) 2.91
Return on Capital (%) 3.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.70
Total Assets 6957.96
Total Liabilities 6957.96
Total Equity 4056.82
Share Outstanding 538650925
Price to Book Ratio 3.89
Return on Assets (%) 10.92
Return on Capital (%) 13.25
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 40.56
Total Assets 6608.53
Total Liabilities 6608.53
Total Equity 3388.21
Share Outstanding 537359335
Price to Book Ratio 9.36
Return on Assets (%) 11.35
Return on Capital (%) 14.98
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 38.78
Total Assets 5625.19
Total Liabilities 5625.19
Total Equity 2712.24
Share Outstanding 536602385
Price to Book Ratio 7.16
Return on Assets (%) 16.99
Return on Capital (%) 23.31
Particulars MAR 2025 (Values in Cr)
Net Income 484.29
Cash from Operations 739.19
Cash from Investing -681.72
Cash from Financing 39.28
Net change in Cash -40.79
Free Cash Flow 1380.19
Particulars MAR 2024 (Values in Cr)
Net Income 236.36
Cash from Operations 770.26
Cash from Investing -822.42
Cash from Financing 249.83
Net change in Cash 93.10
Free Cash Flow 1448.57
Particulars MAR 2023 (Values in Cr)
Net Income 1108.94
Cash from Operations 1279.39
Cash from Investing -996.06
Cash from Financing -26.64
Net change in Cash -28.80
Free Cash Flow 2269.55
Particulars MAR 2022 (Values in Cr)
Net Income 1083.85
Cash from Operations 1093.37
Cash from Investing -914.34
Cash from Financing 30.26
Net change in Cash 27.02
Free Cash Flow 1970.21
Particulars MAR 2021 (Values in Cr)
Net Income 1301.11
Cash from Operations 961.50
Cash from Investing -940.99
Cash from Financing 254.70
Net change in Cash 46.71
Free Cash Flow 1650.27
Particulars MAR 2025 (Values in Cr)
Net Income 503.81
Cash from Operations 674.45
Cash from Investing -591.65
Cash from Financing 59.32
Net change in Cash 7.73
Free Cash Flow 1055.13
Particulars MAR 2024 (Values in Cr)
Net Income 301.47
Cash from Operations 756.52
Cash from Investing -756.74
Cash from Financing 139.41
Net change in Cash 41.21
Free Cash Flow 1123.84
Particulars MAR 2023 (Values in Cr)
Net Income 1051.43
Cash from Operations 1149.68
Cash from Investing -735.27
Cash from Financing -185.19
Net change in Cash -38.91
Free Cash Flow 1891.52
Particulars MAR 2022 (Values in Cr)
Net Income 975.41
Cash from Operations 989.31
Cash from Investing -836.61
Cash from Financing 15.19
Net change in Cash 1.55
Free Cash Flow 1750.76
Particulars MAR 2021 (Values in Cr)
Net Income 1274.63
Cash from Operations 920.51
Cash from Investing -899.68
Cash from Financing 243.13
Net change in Cash 37.90
Free Cash Flow 1517.06
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 27.76 1.99 278.64 34.11 / 77.70
BLISS GVS PHARMA LTD 149.35 18.67 1.49 1573.70 101.00 / 184.95
CIPLA LTD 1505.40 23.06 3.89 121589.70 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 338.10 12.94 2.74 995.06 163.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.36 36.36 5.74 278.64 34.11 / 77.70
AMRUTAJAN HEALTH LTD 697.60 39.68 6.17 2016.81 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 10524.65 150.31 34.15 26311.63 6160.25 / 10653.05
BLISS GVS PHARMA LTD 149.35 22.80 1.48 1573.70 101.00 / 184.95

LAURUS LABS LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
666.60 -0.02 redarrow
red-green-graph indicator
1 Bearish
15 Bullish
  • 5 Days 663.20
  • 26 Days 630.20
  • 10 Days 651.10
  • 50 Days 617.30
  • 12 Days 647.00
  • 100 Days 597.80
  • 20 Days 635.50
  • 200 Days 561.00
670.78 PIVOT

First Support

660.57

First Resistance

676.97

Second Support

654.38

Second Resistance

687.18

Third Support

644.17

Third Resistance

693.37

RSI

69.31

ADX

26.41

MACD

16.84

Williams % R

-16.46

Commodity Channel Index (CCI)

108.97

Date

2025-06-13

Week

918497.00

Same Day

407469.00

Month

713078.00

1 Year

1.29

3 Year

1.01

Over 1 Month

11.98%

down

Over 1 Year

51.67%

down

Over 3 Months

16.12%

down

Over 3 Years

8.13%

down

Over 6 Months

16.24%

down

Over 5 Years

45.65%

down

LAURUS LABS LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
35.08%
Promoter Holdings
27.62%
FII
25.51%
DII
11.77%
Promoter Shares(Pledge Percentage)
2.69%
Name Shares Category
M/s. Nsn Holdings (represented By Its Managing Partner, Dr. Satyanarayana Chava) 1.2412674E8 (23.02%) Shareholding of Promoter and Promoter Group
New World Fund Inc 3.5030909E7 (6.5%) Public Shareholding
Smallcap World Fund, Inc 2.293527E7 (4.25%) Public Shareholding
Anukar Projects Private Limited 1.748361E7 (3.24%) Public Shareholding
Life Insurance Corporation Of India 1.4560251E7 (2.7%) Public Shareholding
Chunduru Venkata Lakshmana Rao 1.4310765E7 (2.65%) Shareholding of Promoter and Promoter Group
Sbi Arbitrage Opportunities Fund 9823907.0 (1.82%) Public Shareholding
Akash Bhanshali 7151700.0 (1.33%) Public Shareholding
M/s. Leven Holdings (represented By Its Managing Partner, Mr. Venkata Ravi Kumar Vantaram) 6705000.0 (1.24%) Shareholding of Promoter and Promoter Group
Goldman Sachs Funds - Goldman Sachs India Equity P 6376522.0 (1.18%) Public Shareholding
Kotak Funds - India Midcap Fund 6250000.0 (1.16%) Public Shareholding
Dsp Arbitrage Fund 6241672.0 (1.16%) Public Shareholding
Barclays Wealth Trustees India Private Limited 6169184.0 (1.14%) Public Shareholding
Vanguard Total International Stock Index Fund 5494395.0 (1.02%) Public Shareholding
Satyanarayana Chava 1570000.0 (0.29%) Shareholding of Promoter and Promoter Group
Venkata Ravi Kumar Vantaram 1000000.0 (0.19%) Shareholding of Promoter and Promoter Group
Krishnaveni Vasireddi 201397.0 (0.04%) Shareholding of Promoter and Promoter Group
Hymavathi Vantaram 225000.0 (0.04%) Shareholding of Promoter and Promoter Group
Rama Suryadevara 170000.0 (0.03%) Shareholding of Promoter and Promoter Group
Narasimha Rao Suryadevara 147500.0 (0.03%) Shareholding of Promoter and Promoter Group
Nagamani Thokala 100000.0 (0.02%) Shareholding of Promoter and Promoter Group
Kamala Kommana 100000.0 (0.02%) Shareholding of Promoter and Promoter Group
Chava Narasimha Rao 119675.0 (0.02%) Shareholding of Promoter and Promoter Group
Sekhar Babu Chunduru 100000.0 (0.02%) Shareholding of Promoter and Promoter Group
Chandrakanth Chereddi 42000.0 (0.01%) Shareholding of Promoter and Promoter Group
Krishna Chaitanya Chava 20699.0 (0.0%) Shareholding of Promoter and Promoter Group
Soumya Chava 22940.0 (0.0%) Shareholding of Promoter and Promoter Group
Chava Naga Rani 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

LAURUS LABS LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
02 Nov 2023 0.4 Interim 02 Nov 2023 Equity shares
10 May 2023 1.2 Interim 2 10 May 2023 Equity shares
03 Nov 2022 0.8 Interim 04 Nov 2022 Equity shares
10 May 2022 1.2 Interim 2 11 May 2022 Equity shares
17 Nov 2021 0.8 Interim 18 Nov 2021 Equity shares
11 May 2021 0.8 Interim 3 12 May 2021 Equity shares
08 Feb 2021 0.4 Interim 2 09 Feb 2021 Equity shares
10 Nov 2020 0.8 Interim 11 Nov 2020 Equity shares
01 Jul 2020 1.0 Final 03 Jul 2020 Equity shares
23 Mar 2020 1.5 Interim 25 Mar 2020 Equity shares
03 Jul 2019 1.5 Final 05 Jul 2019 Equity shares
28 Jun 2018 1.5 Final 02 Jul 2018 Equity shares
06 Jul 2017 1.5 Final 10 Jul 2017 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
29 Sep 2020 10.0 2.0 30 Sep 2020
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
08 May 2024 0.4 Interim 2 08 May 2024 Equity shares
02 Nov 2023 0.4 Interim 02 Nov 2023 Equity shares
10 May 2023 1.2 Interim 2 10 May 2023 Equity shares
03 Nov 2022 0.8 Interim 04 Nov 2022 Equity shares
10 May 2022 1.2 Interim 2 11 May 2022 Equity shares
17 Nov 2021 0.8 Interim 18 Nov 2021 Equity shares
11 May 2021 0.8 Interim 3 12 May 2021 Equity shares
08 Feb 2021 0.4 Interim 2 09 Feb 2021 Equity shares
10 Nov 2020 0.8 Interim 11 Nov 2020 Equity shares
01 Jul 2020 1.0 Final 03 Jul 2020 Equity shares
23 Mar 2020 1.5 Interim 25 Mar 2020 Equity shares
03 Jul 2019 1.5 Final 05 Jul 2019 Equity shares
28 Jun 2018 1.5 Final 02 Jul 2018 Equity shares
06 Jul 2017 1.5 Final 10 Jul 2017 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
29 Sep 2020 10.0 2.0 30 Sep 2020

LAURUS LABS LIMITED Share Price

Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007. Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007. Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007. Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016.

Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology. The company also manufactures APIs in oncology and other therapeutic areas, such as anti-asthma, ophthalmology, antidiabetics, cardiovascular, proton pump inhibitors (PPIs) amongst others. With 12 manufacturing facilities - 8 operating facilities in Visakhapatnam, a drug substance unit and a kilo lab in Hyderabad, and two bio facilities in Bengaluru - which are accredited by global regulatory agencies, including the US FDA and WHO, Company ensure the highest quality standards in the production processes.

The company's strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing 'donor-funded access-to-medicines markets' of Sub-Saharan Africa, South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/ cosmeceutical ingredients businesses.

Laurus Labs operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis and Ingredients. Its Generics - API business comprises the development, manufacture and sale of APIs and advanced intermediates; itsGenerics - FDF business comprises the development and manufacture of oral solid formulations; its Synthesis business includes contract development and manufacturing services for global pharmaceutical companies; and its ingredients business comprises the manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors. The company has launched 59 products since its inception in 2005. Its key customers include Aspen Pharmacare Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, NATCO Pharma Limited ('NATCO') and Strides Shasun Limited. As of September 30, 2016, the Company owned 34 patents and had 152 pending patent applications, in several countries.

The company disinvested its 100% stake in Viziphar Biosciences Private Limited vide Agreement dated April 18, 2016, being the effective date of Agreement as April 1, 2016 and therefore Viziphar Biosciences Private Limited ceased to be the Subsidiary of the Company w.e.f. April 1, 2016. Its dedicated manufacturing facility for Aspen was inaugurated and became operational from November 2016.

The company acquired balance 73% of equity shareholding of its Associate Company, namely Sriam Labs Private Limited with effect from November 1, 2016, thereby Sriam Labs Private Limited became 2nd 100% wholly Owned Subsidiary of the Company. Sriam Labs Private Limited is a private limited company based in India and engaged in design, development and manufacture of Active pharmaceutical intermediates and Intermediates to cater to the needs of pharmaceutical industry, in exchange for cash. The Group acquired Sriam Labs Private Limited because it will help realize the anticipated growth opportunities and synergies from combining these businesses.

During the year ended 31 March 2017, the company expanded its R&D Centre at Hyderabad. It initiated ARV API supply into the European market. USFDA and WHO-Geneva Inspections at the company's Unit-2 was completed. It signed a contract with Dr. Reddy's Lab for the development and marketing of several anti-retroviral formulations on profit and cost sharing basis.

Under Profit sharing arrangement between Laurus Labs and Natco for Hepatitis-C Segment, Natco launched Velpatasvir and Sofosbuvir combination in Nepal and launched in India in May 2017. During the year ended 31 March 2017, Laurus Labs signed manufacturing and supply agreement for Oncology NCE for clinical phase and commercial supplies. During the year under review, the company filed 3 ANDAs with USFDA and one dossier with WHO-Geneva.

During the year 2019, the Company commenced commercial operations from Unit 4 and Unit 5.

During the year 2019, the company incorporated a step down subsidiary in Germany.

During the year 2019, the company's Unit 6 USFDA inspection was completed successfully with one observation.

In FY19, Company launched Tenofovir, Metformin in US, Tenofovir in Canada, DLT (a three-product combination product) in LMIC countries under partnership with Global Fund for treatment of HIV/AIDS. Also, it commenced supply to Europe under contract manufacturing.


In FY 2020, the Company launched Hydroxychloroquine in the United States. It completed backward integration in gemcitabine oncology API. It initiated TLD supplies for the Global Fund tender.

During the year 2021, Company acquired a 72.55% stake in Richcore Lifesciences from two private equity funds, Eight Roads and Ventureast and became its subsidiary. It launched TLE400 in the LMIC market. It partnered with a leading generic player in the EU region for contract manufacturing opportunities. It commenced marketing of in-licensed products. It participated with global fund tenders such as PEPFAR, WHO and various African in-country tenders. It completed four drug product validations, apart from the filing of 27 ANDAs and NDAs. It began construction of large formulation manufacturing block which will be available for commercial use starting Q3 2021. It started 3 new manufacturing blocks for commercial manufacturing of intermediates and APIs. It created additional formulation capacity by de-bottlenecking operations. It acquired a company in South Africa and renamed it as Laurus Generics (SA) Pty Ltd. to cater to the needs to South African Market. It has purchased 18 acres of land in Hyderabad to set up a greenfield Finished Dosage Forms Unit.

During the year 2021, Company's wholly-owned subsidiary i.e, Laurus Synthesis Inc., USA merged into Laurus Generics Inc., USA, which was a step down subsidiary of the Company.

During the year 2022, Company acquired 26.62% of stake in Immunoadoptive Cell Therapy Private Limited, with around Rs. 46 crore investment. During the period 2021-22, Laurus Ingredients Private Limited, a step down subsidiary of the Company was voluntarily strike off from the Regsiter of Companies. It infused more capital into Laurus Generics Inc., due to increase in operations, to a tune of USD 2 Millions.

During the year 2022, it commissioned 1 billion tablets capacity. It signed an agreement with MPP (Medicine Patient Pool) to manufacture Molnupiravir, oral COVID-19 antiviral medication. It acquired lands for two API manufacturing units in Visakhapatnam and one land parcel in Hyderabad for further expansion and its 100% subsidiary, LSPL has acquired two land parcels for manufacturing in Visakhapatnam and one land parcel for its R&D facility in Hyderabad.

During 2022-23, the Company incorporated Laurus Speciality Chemicals Pvt. Ltd., a Wholly Owned subsidiary of Laurus Synthesis Pvt. Ltd. for Specialty Chemicals Business on December 01, 2022. It acquired 26% Stake in Ethan Energy. It commissioned the Unit-2 operation project.

The Company launched NexCAR19, India's pioneering CAR-T cell therapy for B-cell malignancies, advancing the frontiers of medical science in FY24. Two GMP production plants for Animal Health business have started production in 2024. The Company commenced the $40 million Phase I construction of a new GMP-grade microbial fermentation commercial facility in Vizag.

In September 2024, Laurus Labs inaugurated a cutting-edge R&D facility at IKP Knowledge Park, Telangana. The Company acquired 26% equity in Kurnool Renewables to access 26 MW of renewable energy (Solar + wind) on captive model in April, 2025. Company's associate company ImmunoACT, Mumbai treated around 300 patients suffering with Lymphoma and Lukemia with NexCAR-19 and is the first to launch commercial CAR_T therapy and expanding its facilities to create capacity for over 2000 treatments annually in FY 2025.

Parent organization Indian Private
NSE symbol LAURUSLABS
Founded 2005
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Laurus Labs Ltd?

Answer Field

The share price of Laurus Labs Ltd for NSE is ₹ 666.60 and for BSE is ₹ 666.05.

What is the Market Cap of Laurus Labs Ltd?

Answer Field

The market cap of Laurus Labs Ltd for NSE is ₹ 35,946.57 Cr. and for BSE is ₹ 35,916.91 Cr. as of now.

What is the 52 Week High and Low of Laurus Labs Ltd?

Answer Field

The 52 Week High and Low of Laurus Labs Ltd for NSE is ₹ 681.00 and ₹ 414.00 and for BSE is ₹ 680.90 and ₹ 390.30.

How to Buy Laurus Labs Ltd share?

Answer Field

You can trade in Laurus Labs Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Laurus Labs Ltd?

Answer Field

The 1 year returns on the stock has been 51.67%.

What is the Current Share Price of Laurus Labs Ltd?

Answer Field

Laurus Labs Ltd share price is for NSE ₹ 666.60 & for BSE ₹ 666.05 as on Jun 13 2025 03:30 PM.

What is the Market Cap of Laurus Labs Ltd Share?

Answer Field

The market cap of Laurus Labs Ltd for NSE ₹ 35,946.57 & for BSE ₹ 35,916.91 as on Jun 13 2025 03:30 PM.

What is the P/E Ratio of Laurus Labs Ltd Share?

Answer Field

As on Jun 13 2025 03:30 PM the price-to-earnings (PE) ratio for Laurus Labs Ltd share is 94.60.

What is the PB ratio of Laurus Labs Ltd Share?

Answer Field

As on Jun 13 2025 03:30 PM, the price-to-book (PB) ratio for Laurus Labs Ltd share is 84.63.

How to Buy Laurus Labs Ltd Share?

Answer Field

You can trade in Laurus Labs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Laurus Labs Ltd Share on Bajaj Broking App?

Answer Field

To buy Laurus Labs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Laurus Labs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|